摘要
目的观察阿帕替尼治疗晚期肝细胞癌的疗效并进行预后分析。方法选择二线及二线以上治疗失败后的晚期肝细胞癌患者共计30例，使用阿帕替尼治疗直至肿瘤进展或死亡。记录无进展生存期（PFS）、生存期（OS）、客观缓解率（OR）、疾病控制率（DCR）及不良反应。结果30例患者均进行疗效评价，其中部分缓解（Prt）占6．67％（2／30）、疾病稳定（SD）占36．67（11／30）、疾病进展（PD）占56．67％（17／30），无完全缓解（CR）；OR为6．67％、DCR为43．34％、中位PFS为4．17个月、中位OS为9．3个月。分层分析显示，甲胎蛋白（AFP）阳性肝癌患者与AFP阴性者相比，PFS差异有统计学意义（P〈0．05）。主要不良反应为高血压。结论阿帕替尼对晚期肝细胞癌治疗效果好，耐受性好。
Objective To investigate the clinical efficacy of apatinib in the treatment of advanced hepatocellular carcinoma patients and to analyze the prognosis. Methods A total of 30 advanced hepatocellular carcinoma patients after failure of the second - line or beyond treatment were enrolled in the study. All the patients were orally taken 500 mg/d apatinib until tumor progress or death. Then, the progression free survival （PFS）, overall survival time （OS）, objective response （OR）, disease control rate （DCR） and adverse reactions were recorded. Results All the patients were evalu- ated for therapeutic effects. The complete response （CR） rate was 0 （0/30）. The partial response （PR） rate was 6.67 % （2/30）. The stable disease （SD） rate was 36.67% （11/30）. The progressive disease （PD） rate was 56.67% （17/30）. The OR and DCR rates were 6.67% and 43.34%, respectively. The median PFS time was 4.17 months. The median OS time was 9.30 months. According to stratified analysis, patients with positive fetoprotein （AFP） showed sta- tistical different PFS with negative AFP patients （ P 〈 0. 05 ）. The main adverse reaction was hypertension. Conclusions Apatinib can be adopted to treat patients with advanced hepatocellular carcinoma, with good clinical efficacy and toler-
出处
《徐州医学院学报》
CAS
2017年第3期178-181,共4页
Acta Academiae Medicinae Xuzhou
关键词
阿帕替尼
抗血管生成治疗
肝癌
预后
不良反应
apatinib
anti - angiogenesis therapy
hepatocellular carcinoma
prognosis
adverse reactions
